Extrinsic clotting pathway inhibitors are effective anti‐cancer therapies in in vivo murine studies, with the anti‐human TF antibody CNTO‐859 and several thrombin inhibitors including Dabigatran (a direct oral anticoagulant in wide clinical use for thromboprophylaxis) inhibiting tumor initiation, growth, and metastases.43, 44, 45 Dabigatran also inhibits thrombin‐induced fibroblast activation in vitro.32 This evidence concerns the gene TF and cancer.